Bristlecone Advisors’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $7.28M | Sell |
39,236
-1,340
| -3% | -$230K | 0.61% | 36 |
|
|
2025
Q2 | $6.2M | Sell |
40,576
-6,546
| -14% | -$1.01M | 0.52% | 43 |
|
|
2025
Q1 | $7.81M | Buy |
47,122
+587
| +1% | +$91.8K | 0.64% | 36 |
|
|
2024
Q4 | $6.73M | Sell |
46,535
-1,936
| -4% | -$300K | 0.53% | 43 |
|
|
2024
Q3 | $7.86M | Buy |
48,471
+90
| +0.2% | +$14.3K | 0.63% | 36 |
|
|
2024
Q2 | $7.07M | Buy |
48,381
+3,085
| +7% | +$459K | 0.6% | 34 |
|
|
2024
Q1 | $7.17M | Buy |
45,296
+4,007
| +10% | +$638K | 0.63% | 34 |
|
|
2023
Q4 | $6.47M | Buy |
41,289
+1,511
| +4% | +$232K | 0.65% | 34 |
|
|
2023
Q3 | $6.2M | Buy |
39,778
+1,435
| +4% | +$237K | 0.7% | 33 |
|
|
2023
Q2 | $6.35M | Sell |
38,343
-595
| -2% | -$96K | 0.64% | 36 |
|
|
2023
Q1 | $6.04M | Buy |
38,938
+2,979
| +8% | +$481K | 0.66% | 36 |
|
|
2022
Q4 | $6.35M | Buy |
35,959
+52
| +0.1% | +$8.98K | 0.78% | 30 |
|
|
2022
Q3 | $5.87M | Buy |
35,907
+1,041
| +3% | +$176K | 0.77% | 27 |
|
|
2022
Q2 | $6.19M | Buy |
34,866
+2,376
| +7% | +$423K | 0.76% | 27 |
|
|
2022
Q1 | $5.76M | Buy |
32,490
+2,293
| +8% | +$390K | 0.71% | 33 |
|
|
2021
Q4 | $5.17M | Sell |
30,197
-1,586
| -5% | -$260K | 0.62% | 37 |
|
|
2021
Q3 | $5.13M | Buy |
31,783
+170
| +0.5% | +$29K | 0.67% | 34 |
|
|
2021
Q2 | $5.21M | Sell |
31,613
-598
| -2% | -$99K | 0.7% | 32 |
|
|
2021
Q1 | $5.29M | Sell |
32,211
-2,219
| -6% | -$359K | 0.8% | 30 |
|
|
2020
Q4 | $5.42M | Buy |
34,430
+294
| +0.9% | +$43.4K | 0.86% | 24 |
|
|
2020
Q3 | $5.08M | Sell |
34,136
-843
| -2% | -$125K | 0.93% | 24 |
|
|
2020
Q2 | $4.92M | Buy |
34,979
+3,972
| +13% | +$579K | 1% | 25 |
|
|
2020
Q1 | $4.07M | Sell |
31,007
-5,116
| -14% | -$726K | 0.97% | 22 |
|
|
2019
Q4 | $5.27M | Buy |
36,123
+5,921
| +20% | +$803K | 1.06% | 22 |
|
|
2019
Q3 | $3.91M | Sell |
30,202
-5,887
| -16% | -$776K | 0.95% | 25 |
|
|
2019
Q2 | $5.03M | Buy |
36,089
+5,173
| +17% | +$716K | 1.19% | 21 |
|
|
2019
Q1 | $4.32M | Buy |
30,916
+84
| +0.3% | +$11.3K | 1.21% | 20 |
|
|
2018
Q4 | $3.98M | Sell |
30,832
-1,380
| -4% | -$192K | 1.19% | 19 |
|
|
2018
Q3 | $4.45M | Buy |
32,212
+13,335
| +71% | +$1.77M | 1.12% | 20 |
|
|
2018
Q2 | $2.29M | Sell |
18,877
-2,185
| -10% | -$273K | 0.76% | 29 |
|
|
2018
Q1 | $2.7M | Sell |
21,062
-6,653
| -24% | -$899K | 0.91% | 25 |
|
|
2017
Q4 | $3.87M | Buy |
27,715
+335
| +1% | +$46.7K | 1.23% | 17 |
|
|
2017
Q3 | $3.56M | Buy |
27,380
+105
| +0.4% | +$13.9K | 1.16% | 18 |
|
|
2017
Q2 | $3.61M | Buy |
27,275
+257
| +1% | +$32.8K | 1.22% | 17 |
|
|
2017
Q1 | $3.37M | Sell |
27,018
-994
| -4% | -$119K | 1.18% | 18 |
|
|
2016
Q4 | $3.23M | Buy |
28,012
+1,742
| +7% | +$201K | 1.15% | 22 |
|
|
2016
Q3 | $3.1M | Buy |
+26,270
| New | +$3.19M | 1.12% | 22 |
|
|
2016
Q2 | – | Sell |
-26,820
| Closed | -$2.9M | – | 147 |
|
|
2016
Q1 | $2.9M | Buy |
26,820
+1,520
| +6% | +$157K | 1.15% | 22 |
|
|
2015
Q4 | $2.6M | Buy |
+25,300
| New | +$2.54M | 1.1% | 19 |
|
Other funds holding JNJ
Bristlecone Advisors's JNJ Position: Q3 2025 in Review
Bristlecone Advisors reduced its Johnson & Johnson (JNJ) stake by 3.3% in Q3 2025, selling an estimated $230K and leaving 39,236 shares worth $7.28M. The position accounts for 0.61% of the portfolio, ranked #36.
Bristlecone Advisors first reported a position in JNJ in Q4 2015 and has held it in 39 quarters since. The position peaked at $7.86M in Q3 2024. 4,187 funds tracked by Wall St. Rank hold JNJ as of Q3 2025.
- Bristlecone Advisors held 39,236 shares of Johnson & Johnson worth $7.28M as of Q3 2025.
- Bristlecone Advisors sold 1,340 Johnson & Johnson shares in Q3 2025, an estimated $230K.
- Johnson & Johnson made up 0.61% of Bristlecone Advisors's portfolio in Q3 2025, its #36 holding.
- Bristlecone Advisors first reported a position in Johnson & Johnson in Q4 2015 and has held it in 39 quarters since.
- Bristlecone Advisors's Johnson & Johnson position peaked at $7.86M in Q3 2024.
- 4,187 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.